sj-docx-1-tab-10.1177_1759720X241242852 – Supplemental material for Costotransverse joint ankylosis and their association with syndesmophyte progression in patients with radiographic axial spondyloarthritis

Supplemental material, sj-docx-1-tab-10.1177_1759720X241242852 for Costotransverse joint ankylosis and their association with syndesmophyte progression in patients with radiographic axial spondyloarthritis by Hong Ki Min, Se Hee Kim, Sang-Heon Lee, Hae-Rim Kim and Sang-Hoon Lee in Therapeutic Advances in Musculoskeletal Disease</p

DataSheet1_Population pharmacokinetics of everolimus in patients with seizures associated with focal cortical dysplasia.PDF

Background: Everolimus is an inhibitor of mammalian target of rapamycin complex 1. As mutations in TSC1 and TSC2, which cause partial-onset seizures associated with TSC, were found in focal cortical dysplasia type Ⅱ (FCD Ⅱ) patients, a clinical trial has been performed to explore the efficacy and safety of everolimus in FCD patients. However, no dosage regimen was determined to treat FCD II. To recommend an optimal dose regimen for FCD patients, a population pharmacokinetic model of everolimus in FCD patients was developed.Methods: The data of everolimus were collected from September 2017 to May 2020 in a tertiary-level hospital in Korea. The model was developed using NONMEM® software version 7.4.1 (Icon Development Solutions, Ellicott City, MD, United States).Results: The population pharmacokinetics of everolimus was described as the one-compartment model with first-order absorption, with the effect of BSA on clearance. The final model was built as follows: TVCL = 12.5 + 9.71 × (BSA/1.5), TVV = 293, and TVKA = 0.585. As a result of simulation, a dose higher than 7 mg/m2 is needed in patients with BSA 0.5 m2, and a dose higher than 6 mg/m2 is needed in patients with BSA 0.7 m2. A dose of 4.5 mg/m2 is enough in the population with BSA higher than 1.5 m2 to meet the target trough range of 5–15 ng/mL.Conclusion: Based on the developed pharmacokinetics model, the optimal dose of everolimus in practice was recommended by considering the available strengths of Afinitor disperz®, 2 mg, 3 mg, and 5 mg.</p